Underlying endotoxemia augments toxic responses to chlorpromazine: is there a relationship to drug idiosyncrasy?
about
Drug-induced hepatotoxicity: metabolic, genetic and immunological basisRedox regulation of tumor necrosis factor signalingIntrinsic versus idiosyncratic drug-induced hepatotoxicity--two villains or one?Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicityComparison of TNFα to lipopolysaccharide as an inflammagen to characterize the idiosyncratic hepatotoxicity potential of drugs: Trovafloxacin as an example.Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity.Amiodarone exposure during modest inflammation induces idiosyncrasy-like liver injury in rats: role of tumor necrosis factor-alpha.Role of metabolism in drug-induced idiosyncratic hepatotoxicity.Minimising the potential for metabolic activation in drug discovery.Investigations toward enhanced understanding of hepatic idiosyncratic drug reactions.Coexposure of mice to trovafloxacin and lipopolysaccharide, a model of idiosyncratic hepatotoxicity, results in a unique gene expression profile and interferon gamma-dependent liver injury.Hepatotoxic interaction of sulindac with lipopolysaccharide: role of the hemostatic system.Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME.Role of Inflammatory and Oxidative Stress, Cytochrome P450 2E1, and Bile Acid Disturbance in Rat Liver Injury Induced by Isoniazid and Lipopolysaccharide Cotreatment.Trovafloxacin enhances TNF-induced inflammatory stress and cell death signaling and reduces TNF clearance in a murine model of idiosyncratic hepatotoxicity.Chlorpromazine-induced hepatotoxicity during inflammation is mediated by TIRAP-dependent signaling pathway in miceInflammatory stress and idiosyncratic hepatotoxicity: hints from animal models.Molecular mechanisms of hepatocellular apoptosis induced by trovafloxacin-tumor necrosis factor-alpha interaction.Dexamethasone Pretreatment Alleviates Isoniazid/Lipopolysaccharide Hepatotoxicity: Inhibition of Inflammatory and Oxidative Stress.Trovafloxacin potentiation of lipopolysaccharide-induced tumor necrosis factor release from RAW 264.7 cells requires extracellular signal-regulated kinase and c-Jun N-Terminal Kinase.Animal models of idiosyncratic drug-induced liver injury--current status.Idiosyncratic reactions and metabolism of sulfur-containing drugs.Cis-stilbene glucoside in Polygonum multiflorum induces immunological idiosyncratic hepatotoxicity in LPS-treated rats by suppressing PPAR-γ.Current challenges and controversies in drug-induced liver injury.HepaRG culture in tethered spheroids as an in vitro three-dimensional model for drug safety screening.Bacterial- and viral-induced inflammation increases sensitivity to acetaminophen hepatotoxicity.Modeling xenobiotic susceptibility to hepatotoxicity using an in vitro oxidative stress inflammation model.Characteristic molecular and proteomic signatures of drug-induced liver injury in a rat model.Hepatocyte inflammation model for cytotoxicity research: fructose or glycolaldehyde as a source of endogenous toxins.Synergistic Cytotoxicity from Drugs and Cytokines In Vitro as an Approach to Classify Drugs According to Their Potential to Cause Idiosyncratic Hepatotoxicity: A Proof-of-Concept Study.Lipopolysaccharide and trovafloxacin coexposure in mice causes idiosyncrasy-like liver injury dependent on tumor necrosis factor-alpha.
P2860
Q26991809-3D36E177-98E9-4CB4-AA0E-26AA61C0E486Q33644327-21CA4FBA-FAC4-486A-B15C-FB47296E74B2Q33714926-CB892C71-FE19-4868-8AB6-8DEC7C229A26Q34200596-748D6403-D77A-4178-8671-1F8622910202Q34396165-2280F757-A0B1-4B89-BDB6-8A7AAA8C7BCEQ35026973-AAE9963C-340C-4C57-A16E-D863F893B5E6Q35626791-ACC4A7FC-A74F-42A2-90BB-B547FB20AAEEQ36179528-7145AB4F-C7EA-4218-A9B4-1C2B2AFC50C5Q36572637-A0596514-0615-4FF4-9B0D-EEB744A93C0AQ36662857-D1AEC2B5-06CC-48AB-9BC6-0AEB2579B98AQ37089756-86F75223-ED14-42EB-9F7A-D8F2D62A717AQ37101569-C5C82CE8-8E4B-41F6-9BC2-0C893B53F755Q37121662-4EE74BA7-3A9E-4BAE-9577-B31B3E0170D9Q37203817-536490AD-04E4-436E-93EC-B0FAF11FEA4BQ37343343-83BD8CA3-A277-41C1-9BED-581AE1B0CF9EQ37361104-F27BBACE-5EE4-44DA-9442-8B9E19DF0F3BQ37391731-39CD274B-CF6A-4786-8681-79095F13F8E1Q37411993-284617F0-DB91-4130-A2A9-5282F5819668Q37699610-8F5C222E-5E85-4FA6-9290-EE9C2544191CQ37707739-E747B4E1-FFF5-4FAC-949D-67B7F017BA3CQ37897219-92767A0B-B1E5-4E5B-AC9E-86B497A87F77Q37991021-FFB6AFB8-2054-458A-88F0-0A41D82BFA22Q38709657-AFEFC6C8-8B97-4860-AAF5-AF7B681E0BEEQ39523252-31817D44-5984-460B-AB88-DFD66D04A48EQ42703170-1097B8E9-EA12-41B8-89E6-150C03BFE133Q43232351-763E0F17-1498-44B2-959F-E4465A9CC5FDQ43656405-DCA6C9DD-BF40-4CC2-9BFF-00FC7693CF7BQ44380493-A49B89ED-B6F2-4492-8D9A-266F46C73E15Q45988063-0F99DFFC-B56A-4CA1-8CEB-747CF85B5C42Q50902309-3C838DDA-3F01-485C-9DFE-96071D1E78D1Q54435973-10A35869-F4C7-427A-B52D-56335DFD1203
P2860
Underlying endotoxemia augments toxic responses to chlorpromazine: is there a relationship to drug idiosyncrasy?
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Underlying endotoxemia augment ...... tionship to drug idiosyncrasy?
@en
Underlying endotoxemia augment ...... tionship to drug idiosyncrasy?
@nl
type
label
Underlying endotoxemia augment ...... tionship to drug idiosyncrasy?
@en
Underlying endotoxemia augment ...... tionship to drug idiosyncrasy?
@nl
prefLabel
Underlying endotoxemia augment ...... tionship to drug idiosyncrasy?
@en
Underlying endotoxemia augment ...... tionship to drug idiosyncrasy?
@nl
P2093
P356
P1476
Underlying endotoxemia augment ...... tionship to drug idiosyncrasy?
@en
P2093
John P Buchweitz
Patricia E Ganey
Robert A Roth
Steven J Bursian
P304
P356
10.1124/JPET.300.2.460
P407
P577
2002-02-01T00:00:00Z